Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850028 | 0.86 | RIPK1 (0.49) | KMT2AMEN1RIPK1MAPTSMN1; SMN2 | |
| SCHEMBL3971356 | 0.76 | SLC6A4 (0.47) | KMT2AMEN1HDAC1SMN1; SMN2CYP3A4 | |
| SCHEMBL920120 | 0.75 | PPARA (0.41) | KMT2AMEN1MAPTKDM4E | |
| SCHEMBL919800 | 0.74 | F2 (0.48) | KMT2AMEN1RAB9AF2 | |
| SCHEMBL19227135 | 0.73 | CYP2C19 (0.51) | KMT2AMEN1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL24965924 | 0.72 | RIPK1 (0.51) | KMT2AMEN1RIPK1MAPTSMN1; SMN2 | |
| SCHEMBL21605451 | 0.72 | RIPK1 (0.51) | KMT2AMEN1RIPK1MAPTSMN1; SMN2 | |
| SCHEMBL17161705 | 0.72 | RIPK1 (0.53) | KMT2ARIPK1MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL3458542 | 0.72 | RIPK1 (0.45) | KMT2AMEN1RIPK1SMN1; SMN2CYP3A4 | |
| SCHEMBL21538589 | 0.71 | RIPK1 (0.47) | KMT2AMEN1RIPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-7872127-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2201945-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2201944-A2 | Substituted 2-Aminoacetamides and the Use Thereof | Purdue Neuroscience Company (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090240053-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541465-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7393872-B2 | Sodium channel blocker compositions and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-07-01 | — | — | US | disclosed |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-7091210-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | disclosed |
| US-6500825-B2 | SODIUM CHANNEL BLOCKERS USED TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS, LOCAL ANESTHETICS AND ANTIARRHYTHMICS | EURO-CELTIQUE S.A. (LU) | 2002-12-31 | — | — | US | disclosed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240053-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | KMT2A 889/4885MEN1 4823/4885RIPK1 4804/4885 |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | KMT2A 4185/4885MEN1 3719/4885RIPK1 4360/4885 |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | KMT2A 671/4885MEN1 3675/4885RIPK1 4867/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | KMT2A 4185/4885MEN1 3719/4885RIPK1 4360/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | KMT2A 662/4885MEN1 4844/4885RIPK1 4587/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | KMT2A 845/4885MEN1 4788/4885RIPK1 4790/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | KMT2A 671/4885MEN1 3675/4885RIPK1 4867/4885 |
| US-20060217403-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | KMT2A 889/4885MEN1 4823/4885RIPK1 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.